A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss, Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 1/20/2017 |
| Start Date: | October 2006 |
| End Date: | May 2007 |
A Single-Blind, Randomized, Placebo Controlled, Ascending Single and Repeat Dose Study With Once Daily Dosing to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 and to Evaluate Food Effects and the Relative Bioavailability of a Tablet Formulation Compared to the Powder for Reconstitution Formulation in Healthy Overweight and Obese Subjects (DIX109177)
This study represents the first administration of GSK376501 in humans and the goal is to
evaluate its initial safety and tolerability. The way the human body processes GSK376501
will also be determined.
evaluate its initial safety and tolerability. The way the human body processes GSK376501
will also be determined.
A Single-Blind, Randomized, Placebo Controlled, Ascending Single and Repeat Dose Study with
Once Daily Dosing to Evaluate the Safety, Tolerability, Pharmacokinetics, and
Pharmacodynamics of GSK376501 and to Evaluate Food Effects and the Relative Bioavailability
of a Tablet Formulation Compared to the Powder for Reconstitution Formulation in Healthy
Overweight and Obese Subjects (DIX109177)
Once Daily Dosing to Evaluate the Safety, Tolerability, Pharmacokinetics, and
Pharmacodynamics of GSK376501 and to Evaluate Food Effects and the Relative Bioavailability
of a Tablet Formulation Compared to the Powder for Reconstitution Formulation in Healthy
Overweight and Obese Subjects (DIX109177)
Inclusion:
- Healthy
- Non-smoking
- Overweight or obese subjects with a BMI between 27 and 35.
Exclusion:
- Women who are pregnant, lactating, or are of child-bearing potential
We found this trial at
1
site
Click here to add this to my saved trials
